Compounded peptides and medications
A compounded medication is prepared by a licensed pharmacy for an individual prescription rather than manufactured in a factory. It's how providers prescribe compounded peptides and other molecules that have no commercial version and adjust formulations to a patient — and it comes with its own rules: compounded medications are not FDA-approved, and quality depends on the pharmacy's standards.
These articles explain how compounding works, how it's regulated, and what that means for the treatments you're prescribed.
226 articles on this topic
-
KPV Peptide Benefits: What the Evidence Shows
KPV's strongest benefit signals are lower inflammatory activity in cultured cells and mouse colitis models. No human trial has established a KPV benefit, dose, or safety profile.
-
LillyDirect Tirzepatide vs Compounded Tirzepatide
LillyDirect supplies branded Zepbound in fixed-strength single-dose vials. Compounded tirzepatide is prepared by a licensed pharmacy for an individual prescription, so it is a different finished product and a different fulfillment route.
-
PT-141 Benefits: What the Human Trials Show
The strongest evidence is specific: studies found higher desire scores and less distress about low desire in premenopausal women with HSDD. Earlier, smaller trials in men measured erectile response, not broad sexual performance.
-
Semaglutide Glycine: Why Some Pharmacies Add It
Semaglutide with glycine is a compounded combination. Glycine may be described as a formulation aid or wellness additive, but no clinical trial shows that the pairing improves semaglutide outcomes.
-
Semaglutide Injections: A Practical Guide
Semaglutide is usually injected once a week, but the device, missed-dose rule, storage window and disposal steps depend on the exact product prescribed.
-
Sermorelin for Weight Loss: What Studies Show
Sermorelin is not a weight-loss drug. It changes growth-hormone signaling, but small older-adult studies found hormone effects without reliable scale-weight loss.
-
Tesamorelin vs CJC-1295: Evidence and Differences
Both peptides signal through the GHRH receptor, but their structures, duration and human evidence differ sharply. The clearest distinction is phase 3 visceral-fat data for tesamorelin versus biomarker studies for CJC-1295.
-
Thymosin Alpha-1 Benefits: What Studies Show
Thymosin alpha-1 has a credible immune-modulating mechanism, but its human evidence is condition-specific and mixed. The strongest trials do not support a blanket promise of stronger immunity.
-
Tirzepatide for Weight Loss: What to Know
Tirzepatide for weight loss is a once-weekly prescription treatment studied alongside diet and physical activity. Here is who SURMOUNT-1 enrolled, what it found, and what long-term care involves.
-
Does Semaglutide Expire? Pens, Vials, and BUDs
Yes, semaglutide expires, but the date depends on whether it is an Ozempic pen, a Wegovy single-dose pen, or a compounded vial. The printed expiration date or beyond-use date always wins.
-
Is Semaglutide the Same as Ozempic?
Ozempic is a Novo Nordisk product that contains semaglutide. Compounded semaglutide may name the same base molecule, but it is not Ozempic and the finished products are not interchangeable.
-
Is Tesamorelin FDA Approved? Not Every Form
Egrifta has an indication-specific approval for adults with HIV and lipodystrophy. Tesamorelin offered here is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation is not FDA-approved.
-
Semaglutide for Weight Loss: What It Involves
Semaglutide for weight loss is a prescription treatment used alongside lower-calorie eating and physical activity. Its effects build over months, and individual results depend on continued treatment, tolerability, and clinical fit.
-
SS-31 Benefits: What Human Trials Actually Show
The clearest human evidence for SS-31 is narrow: muscle-strength findings in people with Barth syndrome. Larger trials in other mitochondrial, heart, and eye conditions have produced mixed or negative primary results.
-
TB-500 Benefits: What the Evidence Shows
TB-500 benefits are biologically plausible but not established in people. Direct evidence is largely laboratory and animal work on a related actin-binding sequence; the human eye and wound trials tested full-length thymosin beta-4, not systemic TB-500.
-
Tirzepatide Injections: A Practical Guide
Tirzepatide injections deliver prescribed tirzepatide under the skin once weekly. The device may be a prefilled pen, a four-dose KwikPen, or a vial used with a syringe, and each format has its own instructions.
-
Does Semaglutide Cause Depression? What We Know
Large trials, cohort studies, and final FDA and European reviews have not found that semaglutide raises depression or suicidality risk. Individual mood changes still deserve prompt attention.
-
GHK-Cu Dosage: How Prescribers Set the Amount
There is no validated human injection dose for GHK-Cu. Topical studies disclose several concentrations, while compounded injection amounts come from clinical practice and must be tied to the exact vial and the person being treated.
-
Semaglutide for Fatty Liver: What Evidence Shows
Semaglutide has strong biopsy-based evidence in adults with MASH and F2–F3 fibrosis. That is narrower than “fatty liver,” and it does not make every semaglutide formulation interchangeable.
-
Thymosin Alpha-1 Side Effects: What Trials Found
Published trials most consistently report local injection-site discomfort; fatigue and rash are uncommon and often hard to attribute. The limits are long-term exposure and the difference between studied thymalfasin and a compounded vial.
Page 8 of 12 · 226 articles